New FDA-Approved Blood Test Brings Hope for Early Alzheimer’s Detection
The Brain and Mind Experts
Dr. Emer MacSweeney and Tom Dent talk about the tests that can diagnose Alzheimer’s. For the first time, the U.S. Food and Drug Administration (FDA) has approved a blood test that can help identify Alzheimer’s disease in clinical practice. For a disease that is a global pandemic, this kind of accessible testing is critical.
info_outline
Traumatic Brain Injury or Early Onset Alzheimer’s?
The Brain and Mind Experts
Retired British professional footballer Ray Clarke, diagnosed with early-onset Alzheimer’s, is participating in a clinical trial to slow or stop the progression of the disease. Drawing on a history of head injuries, Ray joins Dr. Emer MacSweeney, CEO and Medical Director of Re:Cognition Health, and Tom Dent, Executive Chairman of Re:Cognition Health, to urge former contact sport athletes to seek early testing and treatment for neurological issues.
info_outline
Introducing The Brain and Mind Experts
The Brain and Mind Experts
The Brain and Mind Experts podcast is your gateway to the latest breakthroughs in cognitive health. Hosted by Dr. Emer MacSweeney and Tom Dent of Re:Cognition Health, each episode explores the causes, treatments, and emerging solutions for memory loss and neurological disorders like Alzheimer’s. Join us as we bring hope and expert insight to those navigating the complexities of brain health.
info_outline
The Power of Early Action in the Fight Against Alzheimer’s
The Brain and Mind Experts
Dr. Emer MacSweeney and co-founder Tom Dent dive deep into why early diagnosis matters more than ever and how new breakthroughs in biomarkers and treatments are transforming the outlook for millions.
info_outline
The New Hope for Alzheimer’s
The Brain and Mind Experts
Dr. Emer MacSweeney, CEO and Medical Director of Re:Cognition Health, and Tom Dent, Executive Chairman of Re:Cognition Health, discuss major advancements in treating cognitive disorders, including two new breakthough medications for Alzheimer’s. With the first of these revolutionary treatments now available on the market, Re:Cognition Health continues to lead, delivering these medications safely to individuals in both the USA and UK.
info_outlineDr. Emer MacSweeney, CEO and Medical Director of Re:Cognition Health, and Tom Dent, Executive Chairman of Re:Cognition Health, discuss major advancements in treating cognitive disorders, including two new breakthough medications for Alzheimer’s. With the first of these revolutionary treatments now available on the market, Re:Cognition Health continues to lead, delivering these medications safely to individuals in both the USA and UK.